Baozhong Zhang

Baozhong Zhang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
BZBaozhong Zhang
Baozhong Zhang
YLYang Li
Yang Li
LXLi-Ming Xu
Li-Ming Xu
YCYan-Lan Chai
Yan-Lan Chai
CQChao Qu
Chao Qu
JZJiaqi Zhang
Jiaqi Zhang
Objective: The purpose of this study is to verify the correlation between medium and low radiation doses of the pelvic-bone marrow and the incidence of lymphocytic toxicity during concurrent chemoradiotherapy for cervical cancer. Materials and methods: This research included 117 cervical cancer patients, who received concurrent chemoradiotherapy. Radiotherapy included external-beam radiation therapy and brachytherapy. The dosimetry parameters include the Volume receiving 5 Gy (V5), 10 Gy (V10), 20 Gy (V20), 30 Gy (V30), 40 Gy (V40), 50 Gy (V50), and the mean dose (D mean) of the bone marrow. Lymphocytic toxicity was calculated from lowest lymphocytic count after two cycles of concurrent chemotherapy. Results: During concurrent chemoradiotherapy, the incidence of lymphocytic toxicity is 94.88%. The incidence of grade 3–4 toxicity is 68.38%. Multivariate analysis findings show that the dosimetry parameters V5, V10, V20, and V30 are significantly correlated with lymphocytic toxicity. The patients are divided into small-volume subgroups and large-volume subgroups based on the cutoff values. The relative risk of both grade 1–4 and grade 3–4 lymphocytic toxicity is significantly lower in the small-volume subgroups than in the large-volume subgroups (P < 0.05). Kaplan–Meier analysis shows that the incidence of both grade 1–4 and grade 3–4 lymphocytic toxicity of the small-volume subgroups is significantly lower than that of the large-volume subgroups (P < 0.05). Conclusion: There is a significant correlation between a medium and low dose of pelvic-bone-marrow radiation and incidence of lymphocytic toxicity. Reducing the volume of medium and low radiation doses could effectively reduce incidence of lymphocytic toxicity.

25 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
BZBaozhong Zhang
Baozhong Zhang
ZYZhiyong Yuan
Zhiyong Yuan
LZLujun Zhao
Lujun Zhao
QPQingsong Pang
Qingsong Pang
PWPing Wang
Ping Wang
Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients

1 October 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
BZBaozhong Zhang
Baozhong Zhang
LZLujun Zhao
Lujun Zhao
ZYZhiyong Yuan
Zhiyong Yuan
QPQingsong Pang
Qingsong Pang
PWPing Wang
Ping Wang
Objective: The use of postoperative radiotherapy (PORT) remains controversial for Stage IIIA-N2 non-small-cell lung cancer (NSCLC) patients, a possible reason is that IIIA-pN2 NSCLC diseases are a heterogeneous group with different clinicopathologic features. The aim of this research was to prove whether the mediastinal lymph nodes’ (LNs) skipping status could indicate the necessity of the PORT for the pN2 NSCLC patients. Methods: The skip metastasis was defined as pN0N2 (no N1 LN involved), and nonskip metastasis was pN1N2 (one or more N1 LNs involved). Patients were divided into two groups: LNs nonskip and LNs skip, and postoperative chemoradiotherapy (POCRT) and postoperative chemotherapy. Then, the LN nonskip and LN skip groups were further divided into subgroups: POCRT and point of care testing (POCT) for subgroup analysis. Results: There were 220 cases included in the analysis, and 43 of them received PORT. On univariate analysis, the median 3-year progression-free survival (PFS) was, respectively, 16 months (27.7%) for the LN skip group and 11 months (15.3%) for the LN nonskip group (P=0.001). The median 3-year overall survival (OS) was, respectively, 35 months (47.0%) for the LN skip group and 27 months (38.7%) for the LN nonskip group (P=0.025). The median 3-year local recurrence-free survival (LRFS) was, respectively, 25 months (41.0%) for the LN skip group and19 months (29.9%) for the LN nonskip group (P=0.014). The median 3-year distant metastasis-free survival (DMFS) was, respectively, 22 months (32.5%) for the LN skip group and 15 months (20.4%) for the LN nonskip group (P=0.013). The median 3-year PFS was, respectively, 17 months (25.6%) for the POCRT group and 12 months (18.6%) for the POCT group (P=0.037). Although the POCRT group showed better OS, LRFS, and DMFS than the POCT group, the results showed no statistical significance. In subgroup analysis, there was no statistical significance in the Kaplan–Meier analysis between subgroups, but it showed that POCRT resulted in better PFS, OS, and DMFS in both LN skip and LN nonskip subgroups; this advantage was more obvious in the LN skip subgroup. Conclusion: The LN skip status is closely related to the survival of the IIIA-N2 NSCLC disease, and the LN skip patients may get more benefit in PFS and LRFS than the LN nonskip patients from PORT.

6 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Yuanjie CaoYuanjie Cao
Yuanjie Cao
CLChen Li
Chen Li
BZBaozhong Zhang
Baozhong Zhang
JCJie Chen
Jie Chen
Background and purpose: Organ-preservation strategies are increasingly being incorporated into rectal cancer management, but the role of HDR endorectal/endoluminal brachytherapy boost remains less well defined than that of broader non-operative treatment pathways. Existing literature is frequently mixed with contact X-ray brachytherapy series, neoadjuvant protocols with planned surgery, or heterogeneous watch-and-wait cohorts, limiting the interpretation of this specific strategy. Materials and methods: We performed a PROSPERO-registered systematic review and meta-analysis of studies evaluating definitive-intent external beam radiotherapy (EBRT), with or without chemotherapy, followed by HDR endorectal/endoluminal brachytherapy boost in histologically confirmed rectal adenocarcinoma managed without planned surgery. Pooled analyses were performed for clinical complete response (cCR) and late grade ≥3 gastrointestinal (GI) toxicity. Regrowth/local failure outcomes were synthesized descriptively because of heterogeneity in endpoint definitions, denominator selection, and follow-up structure. Results: Six studies were included in the quantitative evidence base, with one additional small feasibility report summarized narratively. The pooled cCR proportion was 69.2% (95% confidence interval [CI], 43.7–86.6). The pooled proportion of late grade ≥3 GI toxicity was 18.1% (95% CI, 10.9–28.6). Reported regrowth/local failure outcomes were not suitable for formal pooling because of inconsistent definitions, differing denominator structures, and non-uniform follow-up frameworks across studies. Conclusion: Current evidence suggests that EBRT plus HDR endorectal/endoluminal brachytherapy boost may represent a selective organ-preservation strategy for carefully chosen patients with rectal adenocarcinoma, particularly where surgery is not feasible or not desired. Its broader clinical use remains limited not only by the small size of the evidence base, but also by fragmented endpoint definitions, inconsistent denominator reporting, and insufficiently standardized durable local-control outcomes. These findings support cautious interpretation of the current evidence and highlight priorities for future prospective studies in rectal cancer management.

7 May 2020 in Research Square
Verified
Preprint
Open access
PDF file
BZBaozhong Zhang
Baozhong Zhang
LXLiming Xu
Liming Xu
ZLZhiyan Liu
Zhiyan Liu
YCYanlan Chai
Yanlan Chai
YCYuanjie Cao
Yuanjie Cao
HHHailing Hou
Hailing Hou
Background: The purpose of this study was to verify the radiation dose of the pelvic bone marrow of different anatomical bony sitesand the incidence of neutrophil toxicity during the concurrent chemoradiotherapy for cervical cancer.Methods: There were 117 cervical cancer patients who received concurrent chemoradiotherapy included in this research. The radiotherapy includedexternal-beam radiation therapy (EBRT) and the brachytherapy. The dosimetric parameters included V5, V10, V20, V30, V40, V50, and Dmean. The final neutrophil count was defined as the lowest neutrophil count after 2 circles of concurrent chemotherapy, during or within 1 month after the treatment. The correlation between the dosimetric parameters and the lowest neutrophil count were analyzed by linear regression, the cutoff values of the dosimetric parameters were obtained using the ROC curves,the patients were divided into subgroups based on the cutoff values. The clinicopathologic features and the dosimetric parameters were included into the multivariate regression analysis model to further prove the correlation between the dosimetric parameters and the neutrophil toxicity. Data were assessed with IBM-SPSS software version 22.0, and all values of p<0.05were considered statistically significant.Results:The neutrophil toxicity (grade 1-4) rate was 58.97%. The linear regression showed the Dmean and V50 of Lumbosacral vertebrae(LS), the Dmean, V5, V10, V20, V30, V40 and V50 of the ilium correlated with the lowest neutrophil count, while none of the dosimetric parameters of the femoral correlated with the lowest neutrophil count.The multivariate analysis showed the V20, V30 and V50 of the LS, the Dmean, V5, V10, V20 and V30 of the ilium correlated well with the neutrophil toxicity; none of the dosimetric parameters of the femoral correlated with the neutrophil toxicity.Conclusion:During the process of concurrent chemoradiotherapy for cervical cancer, the volume of medium and high dose of LS and the volume of low and medium dose of ilium should be strictly limitedto reduce the risk of neutrophil toxicity, the Dmean of the ilium should also be taken into consideration. The dosimetric parameters of the femur could be ignored.Trial registration:This is a retrospective research, and it will be retrospectively registered.